This study tests a new drug called ISB 2001 for people with a type of blood cancer called multiple myeloma, which has come back or hasn't responded to previous treatments. The study is Phase 1, meaning it's the first time this drug is used in humans to check if it's safe and effective. Participants must have already tried other treatments, like immunomodulatory drugs (IMiDs), proteasome inhibitors, and anti-CD38 therapies, but these didn't work or caused bad side effects.
The study has two parts: Part 1 finds the best dose of ISB 2001, and Part 2 checks how well that dose works. Participants will take ISB 2001 until their disease gets worse, they have bad side effects, or they decide to stop.
- Participants may need to visit the study site regularly for monitoring.
- They must not have certain health issues, like brain cancer or uncontrolled infections.
- Women who are pregnant or breastfeeding cannot join.